RNA-Based Therapeutics Market Research Report Information By Type (RNA Interference (RNAi) and RNA Antisense), By Application (Genetic Disorders and Auto Immune Disorders), By End User (Research Institutes and Hospitals & Clinics), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Model

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value Chain Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. GLOBAL RNA BASED THERAPEUTICS MARKET,BY TYPE

6.1. Overview

6.2. RNA Interference (RNAi)

6.3. RNA Antisense

7. GLOBAL RNA BASED THERAPEUTICS MARKET,BY APPLICATION

7.1. Overview

7.2. Genetic Disorders

7.3. Auto immune disorders

8. GLOBAL RNA BASED THERAPEUTICS MARKET,BY END USER

8.1. Overview

8.2. Research Institutes

8.3. Hospitals & Clinics

9. GLOBAL RNA BASED THERAPEUTICS MARKET, BY REGION

9.1. Overview

9.1. North America

9.1.1. US

9.1.2. Canada

9.2. Europe

9.2.1. Germany

9.2.2. France

9.2.3. UK

9.2.4. Italy

9.2.5. Spain

9.2.6. Rest of Europe

9.3. Asia-Pacific

9.3.1. China

9.3.2. India

9.3.3. Japan

9.3.4. South Korea

9.3.5. Australia

9.3.6. Rest of Asia-Pacific

9.4. Rest of the World

9.4.1. Middle East

9.4.2. Africa

9.4.3. Latin America

10. COMPETITIVE LANDSCAPE

10.1. Overview

10.2. Competitive Analysis

10.3. Market Share Analysis

10.4. Major Growth Strategy in the Global RNA Based Therapeutics Market,

10.5. Competitive Benchmarking

10.6. Leading Players in Terms of Number of Developments in the Global RNA Based Therapeutics Market,

10.7. Key developments and Growth Strategies

10.7.1. New ProductLaunch/Service Deployment

10.7.2. Merger &Acquisitions

10.7.3. Joint Ventures

10.8. Major Players Financial Matrix

10.8.1. Sales & Operating Income,2022

10.8.2. Major Players R&D Expenditure.2022

11. COMPANY PROFILES

11.1. Arrowhead Pharmaceuticals

11.1.1. Company Overview

11.1.2. Financial Overview

11.1.3. Products Offered

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. Arbutus Biopharma Corporation

11.2.1. Company Overview

11.2.2. Financial Overview

11.2.3. Products Offered

11.2.4. Key Developments

11.2.5. SWOT Analysis

11.2.6. Key Strategies

11.3. Benitec Biopharma Inc.

11.3.1. Company Overview

11.3.2. Financial Overview

11.3.3. Products Offered

11.3.4. Key Developments

11.3.5. SWOT Analysis

11.3.6. Key Strategies

11.4. Silence Therapeutics plc

11.4.1. Company Overview

11.4.2. Financial Overview

11.4.3. Products Offered

11.4.4. Key Developments

11.4.5. SWOT Analysis

11.4.6. Key Strategies

11.5. Ionis Pharmaceuticals

11.5.1. Company Overview

11.5.2. Financial Overview

11.5.3. Products Offered

11.5.4. Key Developments

11.5.5. SWOT Analysis

11.5.6. Key Strategies

11.6. Gradalis, Inc.

11.6.1. Company Overview

11.6.2. Financial Overview

11.6.3. Products Offered

11.6.4. Key Developments

11.6.5. SWOT Analysis

11.6.6. Key Strategies

11.7. Biogen, Inc

11.7.1. Company Overview

11.7.2. Financial Overview

11.7.3. Products Offered

11.7.4. Key Developments

11.7.5. SWOT Analysis

11.7.6. Key Strategies

11.8. Alnylam Pharmaceuticals, Inc.

11.8.1. Company Overview

11.8.2. Financial Overview

11.8.3. Products Offered

11.8.4. Key Developments

11.8.5. SWOT Analysis

11.8.6. Key Strategies

11.9. Genzyme (Sanofi)

11.9.1. Company Overview

11.9.2. Financial Overview

11.9.3. Products Offered

11.9.4. Key Developments

11.9.5. SWOT Analysis

11.9.6. Key Strategies

11.10. Sarepta Therapeutics

11.10.1. Company Overview

11.10.2. Financial Overview

11.10.3. Products Offered

11.10.4. Key Developments

11.10.5. SWOT Analysis

11.10.6. Key Strategies

12. APPENDIX

12.1. References

12.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL RNA BASED THERAPEUTICS MARKET, SYNOPSIS, 2018-2032

TABLE 2 GLOBAL RNA BASED THERAPEUTICS MARKET, ESTIMATES &FORECAST, 2018-2032(USD BILLION)

TABLE 3 GLOBAL RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)

TABLE 4 GLOBAL RNA BASED THERAPEUTICS MARKET,BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 5 GLOBAL RNA BASED THERAPEUTICS MARKET,BY END USER, 2018-2032 (USD BILLION)

TABLE 6 NORTH AMERICA: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)

TABLE 7 NORTH AMERICA: RNA BASED THERAPEUTICS MARKET,BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 8 NORTH AMERICA: RNA BASED THERAPEUTICS MARKET,BY END USER, 2018-2032 (USD BILLION)

TABLE 9 US: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)

TABLE 10 US: RNA BASED THERAPEUTICS MARKET,BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 11 US: RNA BASED THERAPEUTICS MARKET,BY END USER, 2018-2032 (USD BILLION)

TABLE 12 CANADA: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)

TABLE 13 CANADA: RNA BASED THERAPEUTICS MARKET,BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 14 CANADA: RNA BASED THERAPEUTICS MARKET,BY END USER, 2018-2032 (USD BILLION)

TABLE 1 EUROPE: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)

TABLE 2 EUROPE: RNA BASED THERAPEUTICS MARKET, BY APPLICATION , 2018-2032 (USD BILLION)

TABLE 3 EUROPE: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 4 GERMANY: RNA BASED THERAPEUTICS MARKET,BY TYPE,2018-2032 (USD BILLION)

TABLE 5 GERMANY: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 6 GERMANY: RNA BASED THERAPEUTICS MARKET, BY END USER , 2018-2032 (USD BILLION)

TABLE 7 FRANCE: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)

TABLE 8 FRANCE: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 9 FRANCE: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 10 ITALY: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)

TABLE 11 ITALY: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 12 ITALY: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 13 SPAIN: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)

TABLE 14 SPAIN: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 15 SPAIN: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 16 UK: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)

TABLE 17 UK: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 18 UK: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 19 REST OF EUROPE: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)

TABLE 20 REST OF EUROPE: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 21 REST OF EUROPE: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 22 ASIA-PACIFIC: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)

TABLE 23 ASIA-PACIFIC: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 24 ASIA-PACIFIC: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 25 JAPAN: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)

TABLE 26 JAPAN: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 27 JAPAN: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 28 CHINA: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)

TABLE 29 CHINA: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 30 CHINA: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 31 INDIA: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)

TABLE 32 INDIA: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 33 INDIA: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 34 AUSTRALIA: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)

TABLE 35 AUSTRALIA: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 36 AUSTRALIA: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 37 SOUTH KOREA: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)

TABLE 38 SOUTH KOREA: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 39 SOUTH KOREA: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 40 REST OF ASIA-PACIFIC: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)

TABLE 41 REST OF ASIA-PACIFIC: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 42 REST OF ASIA-PACIFIC: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 43 REST OF THE WORLD: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)

TABLE 44 REST OF THE WORLD: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 45 REST OF THE WORLD: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 46 MIDDLE EAST: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)

TABLE 47 MIDDLE EAST: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 48 MIDDLE EAST: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 49 AFRICA: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)

TABLE 50 AFRICA: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 51 AFRICA: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

TABLE 52 LATIN AMERICA: RNA BASED THERAPEUTICS MARKET,BY TYPE, 2018-2032 (USD BILLION)

TABLE 53 LATIN AMERICA: RNA BASED THERAPEUTICS MARKET, BY APPLICATION, 2018-2032 (USD BILLION)

TABLE 54 LATIN AMERICA: RNA BASED THERAPEUTICS MARKET, BY END USER, 2018-2032 (USD BILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL RNA BASED THERAPEUTICS MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL RNA BASED THERAPEUTICS MARKET

FIGURE 4 GLOBAL RNA BASED THERAPEUTICS MARKET, SHARE (%), BY TYPE, 2022

FIGURE 5 GLOBAL RNA BASED THERAPEUTICS MARKET, SHARE (%), BY APPLICATION, 2022

FIGURE 6 GLOBAL RNA BASED THERAPEUTICS MARKET, SHARE (%), BY END USER, 2022

FIGURE 7 GLOBAL RNA BASED THERAPEUTICS MARKET, SHARE (%), BY REGION, 2022

FIGURE 8 NORTH AMERICA: RNA BASED THERAPEUTICS MARKET, SHARE (%), BY REGION, 2022

FIGURE 9 EUROPE: RNA BASED THERAPEUTICS MARKET, SHARE (%), BY REGION, 2022

FIGURE 10 ASIA-PACIFIC: RNA BASED THERAPEUTICS MARKET, SHARE (%), BY REGION, 2022

FIGURE 11 REST OF THE WORLD: RNA BASED THERAPEUTICS MARKET, SHARE (%), BY REGION, 2022

FIGURE 12 GLOBAL RNA BASED THERAPEUTICS MARKET: COMPANY SHARE ANALYSIS, 2022 (%)

FIGURE 13 ARROWHEAD PHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 14 ARROWHEAD PHARMACEUTICALS: SWOT ANALYSIS

FIGURE 15 ARBUTUS BIOPHARMA CORPORATION.:FINANCIAL OVERVIEW SNAPSHOT

FIGURE 16 ARBUTUS BIOPHARMA CORPORATION.:SWOT ANALYSIS

FIGURE 17 BENITEC BIOPHARMA INC.:FINANCIAL OVERVIEW SNAPSHOT

FIGURE 18 BENITEC BIOPHARMA INC.:SWOT ANALYSIS

FIGURE 19 SILENCE THERAPEUTICS PLC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 20 SILENCE THERAPEUTICS PLC.:SWOT ANALYSIS

FIGURE 21 IONIS PHARMACEUTICALS:FINANCIAL OVERVIEW SNAPSHOT

FIGURE 22 IONIS PHARMACEUTICALS:SWOT ANALYSIS

FIGURE 23 GRADALIS, INC..:FINANCIAL OVERVIEW SNAPSHOT

FIGURE 24 GRADALIS, INC..:SWOT ANALYSIS

FIGURE 25 BIOGEN, INC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 26 BIOGEN, INC: SWOT ANALYSIS

FIGURE 27 ALNYLAM PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 28 ALNYLAM PHARMACEUTICALS, INC.: SWOT ANALYSIS

FIGURE 29 GENZYME (SANOFI).: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 30 GENZYME (SANOFI).: SWOT ANALYSIS

FIGURE 31 SAREPTA THERAPEUTICS.:FINANCIAL OVERVIEW SNAPSHOT

FIGURE 32 SAREPTA THERAPEUTICS.:SWOT ANALYSIS